KL
MDxHealth Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ConfirmMDx | Prostate Cancer (False-Negative Biopsy) | Approved |
| Genomic Prostate Score (GPS) | Prostate Cancer (Risk Stratification) | Approved |
| SelectMDx | Prostate Cancer (Initial Risk Assessment) | Approved |
| ResolveMDx | Urinary Tract Infection (UTI) | Approved |
| ExoDx Prostate Test | Prostate Cancer (Non-Invasive Risk Assessment) | Approved |
Leadership Team at MDxHealth
MK
Michael K. McGarrity
Chief Executive Officer, Director
RK
Ron Kalfus
Interim Chief Financial Officer
JB
John Bellano
Chief Commercial Officer
JS
Joseph Sollee
Executive Vice President of Corporate Development and General Counsel
WV
Wim Van Criekinge
Chief Scientific Officer
KH
Koen Hoffman
Chairman and Independent Director
EB
Eric Bednarski
Independent Director
DH
Don Hardison
Independent Director
MH
Michael Holder
Independent Director
SJ
Sanford J. Siegel
Independent Director